Date: 2015-04-23
Type of information: Development agreement
Compound: antibody for the prevention of inflammatory osteolysis
Company: MRC Technology (UK) NYU School of Medicine (USA - NY)
Therapeutic area: Bone diseases
Type agreement: development
Action mechanism: antibody
Disease: prevention of inflammatory osteolysis
Details: * On April 23, 2015, MRC Technology, an independent life science medical research charity, and NYU School of Medicine have signed an agreement to develop an antibody for the prevention of inflammatory osteolysis (bone breakdown). Drs Bruce Cronstein and Kathryn Moore of NYU School of Medicine have identified key proteins expressed on the surface of osteoclasts in the progression of inflammatory osteolysis. MRC Technology has extensive experience in antibody engineering and under the agreement will generate lead antibodies for testing in osteolysis models, before delivering a candidate antibody with acceptable efficacy in vivo.
Financial terms: Financial terms have not been disclosed.
Latest news:
